NASDAQ:EVLO Evelo Biosciences (EVLO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC Filings About Evelo Biosciences Stock (NASDAQ:EVLO) Get Evelo Biosciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume35 shsAverage Volume7,613 shsMarket Capitalization$2 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Evelo Biosciences, Inc. was a clinical-stage biotechnology company focused on developing orally administered medicines designed to act on the small intestine and influence systemic immune responses. Its approach, known as the SINTAX platform, was intended to use selected microbes or microbial-derived signals to modulate immune activity without requiring traditional systemic drug delivery. The company’s development programs targeted inflammatory and immune-mediated diseases, as well as oncology indications. Its lead candidates included EDP1815, an investigational therapy studied in conditions such as psoriasis and atopic dermatitis, and EDP2939, an investigational program designed to stimulate immune responses for potential use in cancer treatment. Evelo was headquartered in Cambridge, Massachusetts, and conducted clinical development activities through research and trial networks in the United States and other regions. In 2023, the company announced that it was discontinuing clinical development activities, reducing its workforce and evaluating strategic alternatives. As a result, Evelo Biosciences is best understood as a former clinical-stage biotechnology company rather than an active developer with a broad commercial product portfolio.AI Generated. May Contain Errors. Read More Receive EVLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EVLO Stock News HeadlinesEvelo Biosciences Inc.June 24, 2026 | marketwatch.comEvelo BiosciencesApril 5, 2026 | fool.comElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding two or three asymmetric home runs. Analyst Jeff Brown says he has identified a new one, a single stock he calls Elon Musk's One Stock Retirement Plan.October 26 at 1:00 AM | Brownstone Research (Ad)Evelo Biosciences (OTC:EVLO) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comEvelo Biosciences (OTC:EVLO) Stock, Insider Trading ActivityOctober 4, 2024 | benzinga.comEVLO Expands Portfolio with Launch of EVLO SYNERGY - A High-Density 5 MWh Battery Storage SolutionAugust 30, 2024 | ca.finance.yahoo.comEvelo Biosciences, Inc. (EVLO)August 24, 2024 | nz.finance.yahoo.comEvelo Biosciences, a microbiome company launched by Flagship, shuts downNovember 24, 2023 | msn.comSee More Headlines EVLO Stock Analysis - Frequently Asked Questions How were Evelo Biosciences' earnings last quarter? Evelo Biosciences, Inc. (NASDAQ:EVLO) released its quarterly earnings results on Wednesday, October, 27th. The company reported ($12.60) EPS for the quarter, missing analysts' consensus estimates of ($10.80) by $1.80. When did Evelo Biosciences' stock split? Evelo Biosciences shares reverse split on the morning of Friday, June 30th 2023.The 1-20 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Evelo Biosciences IPO? Evelo Biosciences (EVLO) raised $85 million in an initial public offering (IPO) on Wednesday, May 9th 2018. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager. What other stocks do shareholders of Evelo Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evelo Biosciences investors own include Riot Platforms (RIOT), Tesla (TSLA), Ford Motor (F), Nikola (NKLAQ), NIO (NIO), Baidu (BIDU) and BioXcel Therapeutics (BTAI). Company Calendar Last Earnings10/27/2021Today10/26/2026Next Earnings (Estimated)11/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:EVLO CIK1694665 Webwww.evelobio.com Phone(617) 577-0300FaxN/AEmployees66Year Founded2015Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares18,840,000Free Float18,789,000Market Cap$2 thousand OptionableNo Data Beta1.34 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:EVLO) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredForget the AI predictions. Look at the incomeAI predictions are everywhere, but Tim Plaehn is focused on something concrete: income. He's found a small ...Investors Alley | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredAsk a 20 Year Trading Pro Your Stock Questions Live for 5Ross Givens, a market analyst with over 20 years on Wall Street, goes live every Monday at 9 AM ET to break do...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evelo Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
